Comments on the Untoward Effects of Corticosteroids on the Musculoskeletal System.
- Published in:
- Journal of Asthma, 1992, v. 29, n. 6, p. 359, doi. 10.3109/02770909209044798
- By:
- Publication type:
- Article
Works matching AU Lieberman, Phil
Results: 17
1
2
IgE mediated hypersensitivity to pancreatic extract (PE) in parents of cystic fibrosis (CF) children.
- Published in:
- Clinical & Experimental Allergy, 1979, v. 9, n. 2, p. 125, doi. 10.1111/j.1365-2222.1979.tb01531.x
- By:
- Publication type:
- Article
3
Mast Cells and Anaphylaxis.
- Published in:
- Current Allergy & Asthma Reports, 2016, v. 16, n. 3, p. 1, doi. 10.1007/s11882-016-0598-5
- By:
- Publication type:
- Article
4
Mast Cells and Anaphylaxis.
- Published in:
- Current Allergy & Asthma Reports, 2016, v. 16, n. 2, p. 1, doi. 10.1007/s11882-016-0598-5
- By:
- Publication type:
- Article
5
Nonallergic Rhinitis.
- Published in:
- Current Allergy & Asthma Reports, 2014, v. 14, n. 6, p. 1, doi. 10.1007/s11882-014-0439-3
- By:
- Publication type:
- Article
6
The risk and management of anaphylaxis in the setting of immunotherapy.
- Published in:
- American Journal of Rhinology & Allergy, 2012, v. 26, n. 6, p. 469, doi. 10.2500/ajra.2012.26.3811
- By:
- Publication type:
- Article
7
Mast cell disorders and idiopathic anaphylaxis: Evaluation and management.
- Published in:
- Allergy & Asthma Proceedings, 2020, v. 41, n. 2, p. 90, doi. 10.2500/aap.2020.41.190023
- By:
- Publication type:
- Article
8
Idiopathic anaphylaxis.
- Published in:
- Allergy & Asthma Proceedings, 2014, v. 35, n. 1, p. 17, doi. 10.2500/aap.2014.35.3717
- By:
- Publication type:
- Article
9
Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis.
- Published in:
- Allergy & Asthma Proceedings, 2012, v. 33, n. 6, p. 450, doi. 10.2500/aap.2012.33.3626
- By:
- Publication type:
- Article
10
Two-week comparison study of olopatadine hydrochloride nasal spray 0.6% versus azelastine hydrochloride nasal spray 0.1% in patients with vasomotor rhinitis.
- Published in:
- Allergy & Asthma Proceedings, 2011, v. 32, n. 2, p. 151, doi. 10.2500/aap.2011.32.3439
- By:
- Publication type:
- Article
11
Objective measures of asthma control: Sputum eosinophils, nitric oxide, and other inflammatory mediators.
- Published in:
- Allergy & Asthma Proceedings, 2007, v. 28, n. 5, p. 510, doi. 10.2500/aap2007.28.3039
- By:
- Publication type:
- Article
12
The unusual suspects: A surprise regarding reactions to omalizumab.
- Published in:
- Allergy & Asthma Proceedings, 2007, v. 28, n. 3, p. 259, doi. 10.2500/108854107781285717
- By:
- Publication type:
- Article
13
The effects of repeat omalizumab administration on skin test positivity and the assessment of the safety of administration in patients with positive skin tests to mouse antigen.
- Published in:
- Allergy & Asthma Proceedings, 2007, v. 28, n. 3, p. 320, doi. 10.2500/aap.2007.28.3005
- By:
- Publication type:
- Article
14
Current controversies and challenges in allergic rhinitis management.
- Published in:
- Expert Review of Clinical Immunology, 2015, v. 11, n. 11, p. 1205, doi. 10.1586/1744666X.2015.1081814
- By:
- Publication type:
- Article
15
Clinical Immunology (Book).
- Published in:
- 1977
- By:
- Publication type:
- Book Review
16
Allergy Management in Clinical Practice.
- Published in:
- 1974
- By:
- Publication type:
- Book Review
17
Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis.
- Published in:
- International Archives of Allergy & Immunology, 2013, v. 161, n. 4, p. 369, doi. 10.1159/000351404
- By:
- Publication type:
- Article